Company updateBusiness Standard
Ichnos Glenmark files US FDA application for solid tumour drug
Positive+192 sources
GreyOak summary
Ichnos Glenmark Innovation, a joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, submitted an investigational new drug application to the US FDA for ISB 2301. This first-in-class pentaspecific molecule targets solid tumours and is planned for a Phase I clinical trial in 2027. The submission marks a milestone in expanding the company's oncology pipeline beyond blood cancers.
What it affects
- Glenmark PharmaceuticalsGLENMARKPositive +19
Joint venture filed US FDA applicationRolling sentiment Neutral -6
Source
Read the original at Business StandardMore Glenmark Pharmaceuticals news
- Glenmark launches generic Inlyta for kidney cancer in USEconomic Times · Company update ·
- Glenmark shares rise after US arm launches cancer therapyCNBC-TV18 · Stock view ·